Diabetic Neuropathy Treatment Market: By Disorder Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, and Focal Neuropathy), By Drug Class (Non-Steroidal Anti-Inflammatory Drugs, Opioids, Anti-Depressants, Anti-Seizure, and Others) and By Geography (North America, Europe, Asia Pacific, Latin America, and MEA), and Forecast to 2030.

Purchase Option

$ 4400
$ 6600
$ 8900

Diabetic Neuropathy Treatment Market size was valued at USD 4,183.7 million in 2023 and is projected to reach USD 6,249.3 million by 2030 at a CAGR of 5.9% from 2024 to 2030. Diabetic neuropathy arises from prolonged, uncontrolled high blood sugar levels, predominantly associated with clinical diabetic conditions. Elevated glucose levels can inflict damage on nerves throughout the body, primarily affecting those in the legs and feet. Symptoms range from pain and numbness in the extremities to complications in various bodily systems such as digestion, urinary function, and cardiovascular health. With the World Health Organization projecting a significant increase in diabetes cases, reaching 438 million by 2030, the market for diabetic neuropathy treatment is expected to expand. Factors driving this growth include heightened awareness of diabetes management, the introduction of new treatment options, and the demand for innovative drug delivery methods. Additionally, factors like the ageing population, lifestyle changes, and ongoing research contribute to market expansion. However, challenges such as high product costs and alternative treatment availability hinder growth prospects.

Recent Developments of the Market:

  • In December 2023, Vertex Pharmaceuticals received approval from the U.S. FDA for CRISPR-based gene editing therapy to emphasize the promotion and development of non-opioid pain management drugs.
  • In January 2023, NeuroMetrix commercially launched its new DPNCheck 2.0 point-of-care device for detecting peripheral neuropathy. The new quick, accurate, quantitative test uses nerve conduction technology to detect peripheral neuropathy, the systemic degeneration of peripheral nerves.
  • In January 2023, Neuralace Medical Inc., a medical technology company announced the enrolment of the first patients for its Axon Therapy and Painful Diabetic Neuropathy (AT-PDN) study with a target of around 80 patients. The study was estimated to be conducted at five clinical sites and led by Dr. Lora Brown at TruWell Health, Florida.

Diabetic Neuropathy Treatment Market Summary

Study Period

2024 - 2030

Base Year

2023

CAGR

5.9%

Largest Market

North America

Fastest Growing Market

Asia pacific
Diabetic Neuropathy Treatment Market Dynamics

The high prevalence of diabetes is fueling the diabetic neuropathy market size. As per the American Diabetes Association, 366 million individuals in the U.S. are likely to contract diabetes by 2030. An unhealthy lifestyle is among the key factors driving the diabetes neuropathy industry. According to the International Diabetes Federation, 783 million individuals worldwide may suffer from diabetes by 2045. As per the Centres for Disease Control and Prevention (CDC), physical inactivity, poor nutrition, and stress are the key factors responsible for the proliferation of diabetic neuropathy. As per the World Health Organization (WHO), 35% of the global population is affected by stress. Research states that higher levels of stress hormones are likely to stop insulin-producing cells in the pancreas from functioning normally, thereby reducing the quantity of insulin they produce. This may, in turn, contribute toward the development of type 2 diabetes. The increasing geriatric population across the world is also slated to contribute to the growing prevalence of diabetes and diabetic neuropathy on a global level going forward. As per the statistics listed in the International Diabetes Federation (IDF), nearly 643 million people are anticipated to be suffering from diabetes by the end of 2030. Nearly 90% of these people are expected to be living with type 2 diabetes.

Diabetic Neuropathy Treatment Market Segmentation

By Disorder Type
  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy
By Geography
  • North America
  • Europe
  • The Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The global diabetic neuropathy market was valued at USD 4,183.7 million in 2023 and is projected to reach USD 6,249.3 million by 2030 at a CAGR of 5.9% from 2024 to 2030.

The key players adopted in the diabetic neuropathy treatment market are Abbott Laboratories, Hoffmann-La Roche Ltd, Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline Plc, Lupin Limited, Glenmark Pharmaceuticals Limited, Depomed, Inc., Astellas Pharma Inc, Pfizer Inc, MEDA Pharma GmBH & Co. KG, Janssen Pharmaceutics, Inc., NeuroMetrix Inc., Arbor Pharmaceuticals LLC, and Boehringer Ingelheim Gmbh.

The growing prevalence of diabetes is the major driver for the market.

Challenges such as high product costs and alternative treatment availability hinder growth prospects.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.
1. Executive Summary
2. Global Diabetic Neuropathy Treatment Market Introduction 
2.1.Global Diabetic Neuropathy Treatment Market  - Taxonomy
2.2.Global Diabetic Neuropathy Treatment Market  - Definitions
2.2.1.Disorder Type
2.2.2.Region
3. Global Diabetic Neuropathy Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Diabetic Neuropathy Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Diabetic Neuropathy Treatment Market  By Disorder Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Peripheral Neuropathy
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Autonomic Neuropathy
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Proximal Neuropathy
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Focal Neuropathy
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6. Global Diabetic Neuropathy Treatment Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. North America
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Europe
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Asia Pacific (APAC)
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Middle East and Africa (MEA)
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Latin America
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7. North America Diabetic Neuropathy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Disorder Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
7.1.1.Peripheral Neuropathy
7.1.2.Autonomic Neuropathy
7.1.3.Proximal Neuropathy
7.1.4.Focal Neuropathy
7.2.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
7.2.1.United States of America (USA)
7.2.2.Canada
8. Europe Diabetic Neuropathy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Disorder Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Peripheral Neuropathy
8.1.2.Autonomic Neuropathy
8.1.3.Proximal Neuropathy
8.1.4.Focal Neuropathy
8.2.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Germany
8.2.2.France
8.2.3.Italy
8.2.4.United Kingdom (UK)
8.2.5.Spain
8.2.6.Rest of EU
9. Asia Pacific (APAC) Diabetic Neuropathy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Disorder Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Peripheral Neuropathy
9.1.2.Autonomic Neuropathy
9.1.3.Proximal Neuropathy
9.1.4.Focal Neuropathy
9.2.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.China
9.2.2.India
9.2.3.Australia and New Zealand (ANZ)
9.2.4.Japan
9.2.5.Rest of APAC
10. Middle East and Africa (MEA) Diabetic Neuropathy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Disorder Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Peripheral Neuropathy
10.1.2.Autonomic Neuropathy
10.1.3.Proximal Neuropathy
10.1.4.Focal Neuropathy
10.2.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.GCC Countries
10.2.2.South Africa
10.2.3.Rest of MEA
11. Latin America Diabetic Neuropathy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Disorder Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Peripheral Neuropathy
11.1.2.Autonomic Neuropathy
11.1.3.Proximal Neuropathy
11.1.4.Focal Neuropathy
11.2.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Brazil
11.2.2.Mexico
11.2.3.Rest of LA
12. Competition Landscape
12.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
12.2.1.Abbott Laboratories
12.2.2.Hoffmann-La Roche Ltd
12.2.3.Eli Lilly and Company
12.2.4.Johnson & Johnson
12.2.5.GlaxoSmithKline Plc
12.2.6.Lupin Limited
12.2.7.Glenmark Pharmaceuticals Limited
12.2.8.Depomed, Inc.
12.2.9.Astellas Pharma Inc
12.2.10.Pfizer Inc
12.2.11.MEDA Pharma GmBH & Co. KG
12.2.12.Janssen Pharmaceutics, Inc.
12.2.13.NeuroMetrix Inc.
12.2.14.Arbor Pharmaceuticals LLC
12.2.15.Boehringer Ingelheim Gmbh
13. Research Methodology 
14. Appendix and Abbreviations 
  • Abbott Laboratories
  • Hoffmann-La Roche Ltd
  • Eli Lilly and Company
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • Lupin Limited
  • Glenmark Pharmaceuticals Limited
  • Depomed, Inc.
  • Astellas Pharma Inc
  • Pfizer Inc
  • MEDA Pharma GmBH & Co. KG
  • Janssen Pharmaceutics, Inc.
  • NeuroMetrix Inc.
  • Arbor Pharmaceuticals LLC
  • Boehringer Ingelheim Gmbh

Adjacent Markets